Big biotech, Biotech, Deals, Partnering

Big biotech, Enzo Biochem markets prenatal screening test

Posted on 30 October 2013

Tags: , , ,

Enzo Biochem, big biotech, enters into marketing agreement with Sequenom Laboratories for MaterniT21 PLUS

The Enzo Clinical Lab, subsidiary of big biotech, Enzo Biochem, has entered into an agreement to market early non-invasive prenatal laboratory test service, MaterniT21 PLUS, developed by the Sequenom Laboratories.

Sequenom Laboratories was the first to market a noninvasive prenatal laboratory-developed test for fetal chromosomal abnormalities.

The MaterniT21 PLUS test analyzes the relative amount of 21, 18, 13, as well as X and Y chromosomal material in cell-free DNA.

The test is intended for use in pregnant women at increased risk for fetal aneuploidy, can be used as early as 10 weeks' gestation

For further deal information visit Current Agreements (subscription required)



Read: more on Enzo Biochem company profile

Browse: Complete Current Partnering report catalog

View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value

View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making

View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity

View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity

Signup: Current Partnering Dealmakers Update – weekly newsletter providing the latest life science industry deal news, deal making trends, partnering events – sign up now

Signup: Current Agreements Deals Review – monthly newsletter - reviewing the previous month’s life science deal making – partnering, M&A and financing – sign up now

Subscribe: Current Agreements life sciences partnering, M&A and financing deals database – find out more

Follow us on: LinkedIn Current Partnering | LinkedIn Business Development Network | @Currentpartner on Twitter

Print Friendly, PDF & Email

Leave a Reply